Patent ID: 7157420
Filing Date: 2007-01-02
Classification: A61K,A61P,C07D,C07K,Y02A

Abstract:
1. A method of treating a subject having an autoimmune disorder selected from the group consisting of lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis, and diabetes mellitus, comprising administering to the subject a therapeutically effective amount of a compound comprising the structure of Formula XV, wherein A is a MetAP-2 inhibitory core; W is O or NR; each R is, independently, hydrogen or alkyl; Z is —C(O)— or -alkylene-C(O)—; P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues connected at the N-terminus to Z; Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is —OR, Q is not hydrogen; or Z is -alkylene-O— or alkylene-N(R)—; P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus; Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen; and pharmaceutically acceptable salts thereof.